Q-omics provides the consensus-scored RN7SL663P profile across patient tissues and cancer cell-line models. RN7SL663P expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RN7SL663P is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, RN7SL663P RNA expression shows 17,443 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, BLCA, and THYM as cancer lineages where RN7SL663P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL663P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL663P survival associations across molecular data types. RN7SL663P RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL663P RNA expression–survival associations across cancer types. High RN7SL663P expression shows unfavorable associations in KIRC, MESO, KIRP and LGG, but favorable associations in HNSC and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RN7SL663P RNA expression.
This table summarizes RN7SL663P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL663P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL663P shows higher tumor expression in BLCA, LIHC, BRCA, KIRC, STAD and HNSC. The BLCA box plot shows higher RN7SL663P RNA expression in tumor versus normal tissue (log2 FC = +0.610, t-test p = .002).
This table shows molecular features associated with RN7SL663P in patient tissues and cancer cell lines. In patient samples, RN7SL663P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
